3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Melanoma
1
Limited Stage Small Cell Lung Cancer
1
Head and Neck Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
8
Paclitaxel
7
Hyperthermic Intraperitoneal Chemotherapy
7
Bevacizumab
4
liposomal doxorubicin
3
Gemcitabine
3
Oxaliplatin
2
Neoadjuvant Therapy
2
relacorilant
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
olaparib
1
nintedanib
1
lobaplatin
1
lanreotide
1
epothilone B
1
atezolizumab
1
Trabectedin
1
Topotecan
1
Therapeutics
1
Surgical Procedures, Operative
1
Saline Solution
1
Leucovorin
1
Letrozole
1
Laparotomy
1
Laparoscopy
1
LAIF 900
1
Hypericum extract LI 160
1
Glucose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Peritoneal Neoplasms
×
Glucose
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts